[COPD inhaled therapy narrative review]

Semergen. 2022 Apr;48(3):214-218. doi: 10.1016/j.semerg.2021.08.001. Epub 2021 Sep 4.
[Article in Spanish]

Abstract

Inhaled therapy with long-acting bronchodilators is the base of pharmacological treatment in COPD. In order to find out those that offer better control, a search was carried out in Medline (Pubmed). Comparative studies of inhaler therapy in COPD patients were analyzed. The comparison between the fixed combination LABA/LAMA versus LABA/CI in non-exacerbating patients, revealed a better control with LABA/LAMA. Within the LABA/CI combinations, budesonide/formoterol combination offered better control. LAMA inhalers revealed no great differences, but when compared to LABA, it offered a better control. Regarding triple therapy in a single device, was superior to double therapy and to triple therapy in two devices, with no relevant differences among the available combinations.

Keywords: Chronic obstructive pulmonary disease; Enfermedad pulmonar obstructiva crónica; Exacerbación; Exacerbation; Inhaler therapy; Terapia inhaladora.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones
  • Adrenergic beta-2 Receptor Agonists*
  • Bronchodilator Agents
  • Drug Combinations
  • Drug Therapy, Combination
  • Humans
  • Muscarinic Antagonists / therapeutic use
  • Pulmonary Disease, Chronic Obstructive* / drug therapy

Substances

  • Adrenal Cortex Hormones
  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents
  • Drug Combinations
  • Muscarinic Antagonists